The tweet was deleted by the author.
But we saved everything 🙂.
Brian Armstrong, CEO of Coinbase, announced that NewLimit has raised an additional $45 million in funding aimed at advancing the development of longevity medicines. This substantial investment comes from major backers including pharmaceutical giant Eli Lilly, Duke University, and S32 Ventures.
The funding injection follows remarkable progress since NewLimit's series B round just five months prior, underscoring growing confidence in the company's potential to deliver transformative healthcare solutions. Armstrong expressed gratitude to these new investors for supporting the mission to enhance human health and extend lifespan.
The confidence shown by new and existing investors in NewLimit aligns with broader trends in innovation and risk appetite across the biotechnology sector. Brian Armstrong’s continued involvement reflects a commitment seen in earlier initiatives, such as his push to expand Coinbase’s reach through efforts like testing enhanced account limits and the ongoing work to integrate digital assets with traditional finance. This latest funding round highlights how leaders at the intersection of technology and finance are increasingly prioritizing advancements that could reshape global health and investment landscapes.